Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Terminated 1Suspended 1

Sponsor Class

OTHER 2NETWORK 2NIH 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 6Sarcoma 1

Conditions

Glioblastoma 4Medulloblastoma 2Recurrence 1Neoplasms 1Gliosarcoma 1

Interventions

Specimen Handling 415Magnetic Resonance Spectroscopy 332pembrolizumab 261Biopsy 227Carboplatin 216Cisplatin 179Cyclophosphamide 174Paclitaxel 148Nivolumab 135Gemcitabine 130Radiotherapy 120Dexamethasone 105Bevacizumab 101fludarabine 95Radiation 94Fluorouracil 93Pemetrexed 88Doxorubicin 88Docetaxel 83Rituximab 82venetoclax 81durvalumab 81Oxaliplatin 81Leucovorin 76atezolizumab 68Lenalidomide 66Capecitabine 66Prednisone 65Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Lomustine × 30 days × Clear all
NCT06325683 2026-05-26

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Suspended
184 enrolled
CNS

Glioblastoma

NCT02724579 2026-05-20

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Children's Oncology Group

Phase 2 Active not recruiting
45 enrolled
CNS

Medulloblastoma

NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

NCT05382338 2026-05-05

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Children's Oncology Group

Phase 3 Recruiting
225 enrolled
CNS

Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡